Indoco Remedies Ltd. has successfully obtained EU GMP certification for its manufacturing facility located at Baddi, following an inspection by the Malta Medicines Authority. The inspection took place from January 29, 2026, to February 3, 2026.
The certification confirms that Indoco’s facility complies with the Good Manufacturing Practice (GMP) requirements as outlined in the EC Directive. This achievement underscores the company’s commitment to maintaining high-quality standards and adherence to global regulatory norms.
Ms. Aditi Panandikar, Managing Director of Indoco Remedies, expressed satisfaction with the certification, stating, “This approval from the Malta Medicine Authority further reflects Indoco’s strong commitment to quality, compliance and adherence to global regulatory standards. We are focused on maintaining the highest quality standards while catering to our customers in India and globally.”
Indoco Remedies is a research-oriented pharmaceutical company with a significant global presence. It operates 10 manufacturing facilities, including six for finished dosage forms (FDFs) and four for active pharmaceutical ingredients (APIs). These facilities have received approvals from major regulatory authorities, including the USFDA and UK-MHRA.
The company’s turnover is US$ 175 million, supported by a workforce of over 6,000 employees, including more than 300 skilled scientists. Indoco develops and manufactures a wide range of pharmaceutical products for both Indian and international markets, generating over 109 million prescriptions annually.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).
This article is written by Business Desk and reviewed by Aman Shukla before publication.